Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q3 2025 Earnings Presentation
13 slides from Heartbeam's earnings presentation, Nov 13, 2025
Slide 1: Third Quarter 2025 Financial Results Conference Call
NASDAQ: BEAT Third Quarter 2025 Financial Results Conference Call Total Heart Intelligence… Wherever You Are NOVEMBER 13, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and
Slide 3: Agenda
Agenda WHAT WE’LL COVER: ON THE CALL TODAY: The HeartBeam System Company Milestones & Progress Commercialization Strategy ROB ENO TIM CRUICKSHANK Financial Results
Slide 4: From symptoms to confidence. Anywhere, anytime.
Our Mission From symptoms to confidence. Anywhere, anytime. HeartBeam is the first ever cable-free synthesized 12-Lead ECG platform, delivering clinical-grade insights in real time, wherever arrhythmia symptoms begin. Freedom: Accuracy: Access: Speed: Diagnose Clinical-grade App-based Rapid anywhere
Slide 5: What Once Lived in Hospitals is Moving into the Home
What Once Lived in Hospitals is Moving into the Home Across medicine, tools once locked inside clinical settings are becoming part of daily life at home. HeartBeam brings that same shift to cardiac care. A MAJOR HEALTHCARE TREND: FROM HOSPITAL TO HOME USE Continuous Glucose Monitoring Blood Pressure
Slide 6: From Arrhythmia Symptoms to Clarity in Minutes
From Arrhythmia Symptoms to Clarity in Minutes • Finalized agreement with HeartNexus as cardiology reader service • US-based, board certified cardiologists with coverage across the U.S. • Will provide on-demand interpretation of HeartBeam’s synthesized 12-lead ECG for arrhythmia assessment and timel
Slide 7: Building the Future of Cardiac Care
Building the Future of Cardiac Care TRENDING INSIGHTS HeartBeam AUTOMATED ASSESSMENTS Ecosystem HeartBeam’s synthesized 12-Lead ECG system, combined with an on-demand cardiologist for arrhythmia assessment, forms the foundation of a new model for cardiac care. AI WEARABLE From this core, we are buil
Slide 8: Continued Achievement of Stated Milestones
Continued Achievement of Stated Milestones Consistent execution over past twelve months. Confident in near-term milestones ahead. Past 12 Months Upcoming Milestones ✓ Foundational FDA Clearance for HeartBeam System for arrhythmia assessment • FDA 510(k) clearance for 12-Lead ECG Synthesis Regulatory
Slide 9: Additional Progress in the Quarter
Additional Progress in the Quarter Laser focused on near-term goals, while progressing our long-term vision. ✓ New data at AHA Scientific Sessions in November 2025 added to the body of scientific evidence supporting HeartBeam’s potential for early heart attack detection Clinical Evidence ✓ An abstra
Slide 10: Building the Foundation for Commercial Launch
Building the Foundation for Commercial Launch Four Pillars of Near-Term Strategy 1 Create New Category 2 Market Entry Establish HeartBeam as the Pilot in two U.S. regions, first personal, cable free, then expand nationally synthesized 12-Lead ECG 3 Commercial Model 4 Retention & Value Establish focu
Slide 11: Financial Discipline Aligned to Achieving Milestones
Financial Discipline Aligned to Achieving Milestones QTR-OVER-QTR CHANGE YEAR-OVER-YEAR CHANGE • Net cash used in operating activities of Quarter Ended Quarter Ended September 30, $3.2M for Q3 2025. $ in Thousands Sep. 30, 2025iii Jun. 30, 2025 2025iii 2024 • 8% decrease quarter-over-quarter. Operat
Slide 12: HeartBeam: Q3 2025 Summary
HeartBeam: Q3 2025 Summary Engaging in final steps with FDA related to the 510(k) submission for 12-lead ECG synthesis software for arrhythmia assessment and anticipate positive update in Q4 2025 Commercial readiness plans accelerating in anticipation of FDA 510(k) clearance Continue to add to body
Slide 13: Q&A / Company Investor Relations
Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050